Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value (VRDN) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2020 to Q4 2025

Type / Class
Equity / Common Stock, $0.01 par value
Symbol
VRDN on Nasdaq
Shares outstanding
95,489,675
Price per share
$33.26
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
107,824,694
Total reported value
$3,355,134,743
% of total 13F portfolios
0.01%
Share change
+12,946,452
Value change
+$460,112,221
Number of holders
228
Price from insider filings
$33.26
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value (VRDN) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Fairmount Funds Management LLC 15% $345,826,621 16,025,330 Fairmount Funds Management LLC 23 Oct 2025
Venrock Healthcare Capital Partners III, L.P. 4.5% $48,373,931 3,575,309 Venrock Healthcare Capital Partners III, L.P. 31 Dec 2024
Commodore Capital LP 3.9% -28% $69,056,000 -$23,738,000 3,200,000 -26% Commodore Capital LP 30 Sep 2025
Deep Track Capital, LP 2.6% $80,163,448 2,524,833 Deep Track Capital, LP 31 Dec 2025
Kynam Capital Management, LP 1.5% -70% $46,689,677 +$46,689,677 1,470,541 Kynam Capital Management, LP 31 Dec 2025

As of 31 Dec 2025, 228 institutional investors reported holding 107,824,694 shares of Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value (VRDN). This represents 113% of the company’s total 95,489,675 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value (VRDN) together control 80% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
FMR LLC 15% 14,384,456 +17% 0.02% $447,644,271
BlackRock, Inc. 6.7% 6,431,923 +18% 0% $200,161,442
VANGUARD GROUP INC 5.9% 5,612,144 +30% 0% $174,649,921
Bellevue Group AG 4.6% 4,358,527 2.6% $135,637,360
Fairmount Funds Management LLC 4.1% 3,914,458 +13% 9.3% $121,817,933
VR ADVISER, LLC 4.1% 3,882,709 0% 6% $120,829,904
STATE STREET CORP 3.6% 3,466,560 +36% 0% $107,879,347
PRICE T ROWE ASSOCIATES INC /MD/ 3.6% 3,439,414 +42% 0.01% $107,036,000
PERCEPTIVE ADVISORS LLC 3.2% 3,042,703 +108% 1.7% $94,688,917
Deep Track Capital, LP 2.6% 2,524,833 -53% 1.8% $78,572,803
NOVO HOLDINGS A/S 2.5% 2,380,000 0% 5.8% $74,065,600
GEODE CAPITAL MANAGEMENT, LLC 2.1% 1,992,174 +13% 0% $62,006,691
BAKER BROS. ADVISORS LP 2.1% 1,971,678 +13% 0.36% $61,358,619
WELLINGTON MANAGEMENT GROUP LLP 2.1% 1,971,411 +76% 0.01% $61,350,310
TANG CAPITAL MANAGEMENT LLC 1.9% 1,792,626 -37% 2.8% $55,786,521
Eversept Partners, LP 1.9% 1,782,235 -7.4% 3.1% $55,463,153
Fisher Asset Management, LLC 1.9% 1,780,284 +48% 0.02% $55,402,437
MORGAN STANLEY 1.8% 1,738,224 +806% 0% $54,093,536
Avoro Capital Advisors LLC 1.6% 1,500,000 0.46% $46,680,000
LOOMIS SAYLES & CO L P 1.6% 1,481,135 -4.5% 0.06% $46,092,921
Kynam Capital Management, LP 1.5% 1,470,541 -67% 3% $45,763,236
Paradigm Biocapital Advisors LP 1.5% 1,443,102 -45% 1.2% $44,909,334
ALLIANCEBERNSTEIN L.P. 1.5% 1,414,181 -24% 0.01% $44,009,313
MARSHALL WACE, LLP 1.4% 1,375,739 +58% 0.04% $42,812,998
GOLDMAN SACHS GROUP INC 1.3% 1,264,047 +65% 0.01% $39,337,143

Institutional Holders of Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value (VRDN) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 107,824,694 $3,355,134,743 +$460,112,221 $31.12 228
2025 Q3 93,206,736 $2,011,267,436 -$24,960,784 $21.58 168
2025 Q2 94,556,649 $1,321,909,936 +$44,977,645 $13.98 169
2025 Q1 91,362,677 $1,231,598,393 -$2,447,073 $13.48 174
2024 Q4 91,041,740 $1,745,285,274 +$57,671,232 $19.17 177
2024 Q3 86,940,196 $1,978,662,594 +$415,185,793 $22.75 163
2024 Q2 69,645,524 $906,163,827 -$23,346,202 $13.01 137
2024 Q1 71,003,475 $1,243,165,734 +$176,083,012 $17.51 134
2023 Q4 60,143,341 $1,309,923,497 +$204,167,783 $21.78 131
2023 Q3 50,192,424 $769,944,861 +$32,705,128 $15.34 122
2023 Q2 47,119,787 $1,121,040,780 +$92,340,222 $23.79 127
2023 Q1 43,068,809 $1,095,674,908 +$43,441,205 $25.44 134
2022 Q4 41,109,026 $1,200,793,517 +$91,003,851 $29.21 122
2022 Q3 37,976,766 $778,702,810 +$213,427,951 $20.51 104
2022 Q2 28,321,810 $327,687,712 +$27,237,558 $11.57 80
2022 Q1 24,929,839 $460,937,688 -$3,304,649 $18.49 71
2021 Q4 23,259,955 $459,848,025 +$113,447,608 $19.77 52
2021 Q3 13,600,109 $223,717,000 +$123,512,129 $16.45 38
2021 Q2 6,003,456 $109,804,000 +$18,416,912 $18.29 24
2021 Q1 5,057,213 $84,503,000 +$80,676,000 $16.71 28
2020 Q4 229,000 $3,767,000 +$3,767,000 $16.46 2